BioMarin Pharmaceutical Inc. BMRN
Latest 10-Q
What changed in BioMarin Pharmaceutical Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Executive-branch trades
1 tradeTrades in BioMarin Pharmaceutical Inc. reported by the President, Cabinet members and other senior executive-branch officials. Amounts are ranges.Form 278-T is the periodic transaction report that senior executive-branch officials file with the Office of Government Ethics. They must report each trade over $1,000 within 30 days of being notified of it, and no later than 45 days after the trade. Amounts are ranges, not exact figures.
| Official | AssetThe form has no ticker column. The asset is shown as the filer wrote it. We add a ticker link only when we could match the asset to a listed company. | Type | Traded | AmountThe form asks for a range, such as $1,001 - $15,000, not an exact amount. A line can be left blank when the filer's note says the amount was not more than $1,000. | Filed | Report |
|---|---|---|---|---|---|---|
| Donald J Trump President of the United States | BIOMARIN PHARMACEUTICAL read from scan | Purchase | Apr 17, 2026 | $1,001 - $15,000 | Jun 25, 2026 | White House report ↗ |
Lobbying
What BioMarin Pharmaceutical Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Lobbying and contracts
$1.5M · — in 12 moWhat BioMarin Pharmaceutical Inc. reported spending on lobbying next to the federal contracts it was awarded, by year.Lobbying: each report counts once. If a report was amended, only the newest version counts. Totals use the company's own report when it files one (it includes payments to hired firms); otherwise the hired firms' reported income. Registrations and reports with no amount are not counted. A firm that hands part of its work to another firm may report the same money as that other firm does; the filings do not allow us to tell. Contracts: each award is counted once, for the company that received it (or its listed parent when only the parent is matched), in the year of its first obligation. The amount is the total obligated to date, so a later increase is counted in the year the award began. Only awards of $1 million or more are collected. Agencies: the offices named on lobbying reports and the awarding agencies of contracts are matched to one department name (the Army, Navy and Air Force count as the Department of Defense; NIH, FDA and CMS as Health and Human Services). An agency is listed under both when the company lobbied it and was awarded a contract by it in the same period. Offices outside this list, and Congress, are not counted as agencies.
Lobbying Federal contractsBoth bars use one dollar scale.
| Gifts by the company's PAC to candidates for Congress. They come from donations to the PAC, not from the company's own funds. | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 2026 (year to date) | $1.1M | 6 | Health issues, Medicare and Medicaid, Tariff bills | HHS, Executive Office of the President, Commerce | — | — | — | — | — |
| 2025 | $1.3M | 11 | Health issues, Medicare and Medicaid, Tariff bills | HHS, Executive Office of the President, Commerce | — | — | — | — | — |
| 2024 | $490.0K | 2 | Health issues, Medicare and Medicaid | — | — | — | — | — | — |
Agencies both lobbied and awarding contracts
No agency appears on both sides in the last 12 months.
Lobbying and contract awards are reported separately; showing them together does not mean one caused the other.
Capitol Hires at BioMarin Pharmaceutical Inc.
30 hiresLobbyists for BioMarin Pharmaceutical Inc. who say they once worked in Congress or the executive branch.
| The covered position the lobbyist says they held: an office of a member of Congress, a committee or an executive-branch body, as written in the filing. The member's name is a link only when exactly one member of Congress fits the name, chamber, first name and years given; otherwise it stays as written. | The lobbying report (LDA form LD-2) that names this lobbyist and office, with a link to it. Report period is the quarter the report covers; Posted is the day it was filed or amended, which can be much later. The same lobbyist is named again on each quarterly report for the same client, so a row is shown once, from the newest report, with the number of filings that name them. | |||
|---|---|---|---|---|
| Brent del Monte | Bliley (House) Member office · House | Leg. Dir | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 8 filings |
| Brent del Monte | Commerce Committee Committee | Sen. Counsel House Energy | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 8 filings |
| John Stone | Oversight Subcommittee Committee | Counsel | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 8 filings |
| John Stone | House E&C Cmte Committee | Senior Counsel | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 8 filings |
| John Stone | Health Subcommittee Committee | Senior Counsel | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 8 filings |
Each row reflects what was disclosed at the time of filing. A lobbyist listed may no longer be registered.
H-1B labor applications at BioMarin Pharmaceutical Inc.
11 certified in 12 moLabor condition applications decided by the Department of Labor, matched to BioMarin Pharmaceutical Inc. by employer name. An application is not a hire.
Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: $148,512The wage the employer offered, as filed, with its unit. The yearly figure restates it per year (hourly x 2,080, weekly x 52, every two weeks x 26, monthly x 12) from the low end of the offered range. It is not what the worker was paid.
| Quarter | Certified | All decided | Workers asked for |
|---|---|---|---|
| 2024 Q3 | 3 | 5 | 3 |
| 2024 Q4 | 4 | 7 | 4 |
| 2025 Q1 | 5 | 6 | 5 |
| 2025 Q2 | 13 | 13 | 13 |
| 2025 Q3 | 4 | 9 | 4 |
| 2025 Q4 | 3 | 3 | 3 |
| 2026 Q1 | 0 | 0 | 0 |
| 2026 Q2 | 4 | 4 | 4 |
| Associate Director, Global Process Leader - Forecast to Plan | 1 | — |
| Associate Director, Site Technical Lead | 1 | — |
| Director “ Global Technology Transfer | 1 | — |
| Director, Molecular Engineering | 1 | — |
| Principal Systems Architect. | 1 | — |
We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Loading…
More filings and data
Each opens the table.
About the company
The basics from the company’s SEC registration.
Loading…
Adjusted for stock splits; not for dividends. Where prices come from.
Live chart
Intraday and historical prices from TradingView. Quotes may be delayed.
Information, not investment advice. Company matching is automatic; check the source before relying on one row.